Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
3.165
+0.445 (16.36%)
Apr 13, 2026, 2:55 PM EDT - Market open
Allogene Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Allogene Therapeutics stock have a consensus rating of "Buy" and an average price target of $8.40, which forecasts a 165.40% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $14.
Price Target: $8.40 (+165.40%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +342.34% | Mar 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +152.76% | Mar 13, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +57.98% | Jan 9, 2026 |
| UBS | UBS | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +152.76% | Jan 7, 2026 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 10, 2025 |
Financial Forecast
Revenue This Year
22.66K
Revenue Next Year
32.69M
from 22.66K
Increased by 144,130.60%
EPS This Year
-0.89
from -0.87
EPS Next Year
-0.82
from -0.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 105,000 | 147.2M | |||
| Avg | 22,664 | 32.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 649,465.0% | |||
| Avg | - | 144,130.6% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.45 | -0.29 | |||
| Avg | -0.89 | -0.82 | |||
| Low | -1.44 | -1.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.